Clinical Trials in Atypical Parkinsonism: Quick Overview

Clinical Trials in Atypical Parkinsonism: Quick Overview

Atypical parkinsonism includes disorders like Progressive Supranuclear Palsy (PSP), Multiple System Atrophy (MSA), Corticobasal Degeneration (CBD), and Dementia with Lewy Bodies (DLB). This post explores clinical trials for these conditions, highlighting advancements, challenges, and the implications for patients and caregivers.

The Landscape of Clinical Trials:

Progressive Supranuclear Palsy (PSP):

Recent Trials:
Tau-Targeted Therapies: Research focuses on tau proteinopathies. Drugs like tideglusib have aimed at inhibiting tau phosphorylation.
Microtubule Stabilizers: TPI-287 seeks to stabilize microtubules to prevent tau aggregates.

Challenges:
Accurate diagnosis and the lack of biomarkers complicate trials.

Multiple System Atrophy (MSA):

Recent Trials:
Immunotherapy: Drugs like PRX002 target alpha-synuclein, with mixed results.
Gene Therapy: Approaches include altering alpha-synuclein expression or degradation.

Challenges:
Heterogeneous symptoms between MSA subtypes make trial design complex.

Corticobasal Degeneration (CBD):

Trials:
Symptomatic Treatment: Botulinum toxin for dystonia, therapy for apraxia.
Tau-Modifying Therapies: Similar to PSP, focusing on tau pathology.

Challenges:
Rarity and diagnostic issues limit large-scale trials.

Dementia with Lewy Bodies (DLB):

Trials:
Cholinesterase Inhibitors and NMDA Antagonists: Standard treatments with ongoing refinement.
Neuroprotective Strategies: Early-stage trials like nilotinib focus on reducing alpha-synuclein.

Challenges:
Overlap with other neurodegenerative diseases complicates patient selection.

Common Challenges Across Disorders:

Diagnosis: Misdiagnosis delays trial participation.
Biomarkers: Lack of specific markers hinders tracking progression or treatment efficacy.
Patient Recruitment: Rarity and diagnostic ambiguity make it hard to gather enough participants.
Disease Heterogeneity: Varied presentations within disorders complicate treatment application.

Future Directions:

Precision Medicine: Personalized treatments based on genetics could improve outcomes.
Combination Therapies: Tackling multiple aspects of these diseases simultaneously.
Improved Diagnostics: Better imaging and biomarkers are essential for precise diagnosis.

Despite the challenges, clinical trials for atypical parkinsonism are advancing our understanding and hope for better treatments. Participation in trials can offer new therapeutic options and contribute to future research. For involvement or support in research, resources like ClinicalTrials.gov are invaluable.

Back to blog

Leave a public comment:

Please note, comments need to be approved before they are published.

  • Introducing the CCF Awareness Shop for Atypical Parkinsonism: Wear It, Share It, Support It

    Introducing the CCF Awareness Shop for Atypical...

    We’re excited to unveil the CCF Coleen Cunningham Foundation Awareness Shop—a new way to raise awareness for atypical parkinsonism and support our mission at the same time! At CCF, we’re...

    Introducing the CCF Awareness Shop for Atypical...

    We’re excited to unveil the CCF Coleen Cunningham Foundation Awareness Shop—a new way to raise awareness for atypical parkinsonism and support our mission at the same time! At CCF, we’re...

  • The Ustep Walker: A Game-Changer for Atypical Parkinsonism

    The Ustep Walker: A Game-Changer for Atypical P...

      The Ustep walker is a specialized mobility aid designed to support individuals with neurological conditions, including atypical Parkinsonism. Unlike standard walkers, the Ustep is engineered with features that address...

    The Ustep Walker: A Game-Changer for Atypical P...

      The Ustep walker is a specialized mobility aid designed to support individuals with neurological conditions, including atypical Parkinsonism. Unlike standard walkers, the Ustep is engineered with features that address...

  • Understanding Atypical Parkinsonism: A Brain Awareness Week Spotlight

    Understanding Atypical Parkinsonism: A Brain Aw...

    As we celebrate Brain Awareness Week this March 2025, it’s the perfect time to shine a light on the incredible complexity of the human brain—and the challenges it faces when...

    Understanding Atypical Parkinsonism: A Brain Aw...

    As we celebrate Brain Awareness Week this March 2025, it’s the perfect time to shine a light on the incredible complexity of the human brain—and the challenges it faces when...

  • Celebrating Brain Awareness Week 2025 with CCF: Shining a Light on Brain Health

    Celebrating Brain Awareness Week 2025 with CCF:...

    At the Coleen Cunningham Foundation (CCF), we’re excited to join the global community in recognizing Brain Awareness Week, running from March 10-16, 2025. This annual campaign, led by the Dana...

    Celebrating Brain Awareness Week 2025 with CCF:...

    At the Coleen Cunningham Foundation (CCF), we’re excited to join the global community in recognizing Brain Awareness Week, running from March 10-16, 2025. This annual campaign, led by the Dana...

1 of 4